LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Inicio・Lista de Acciones・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Cerrado

SectorSalud

18.82 -0.05

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

18.66

Máximo

19.3

Métricas clave
By Trading Economics
Ingresos	-297M -81M
Ventas	-259M 200M
P/B Media del Sector	109.111 61.417
BPA	1.67
Margen de beneficio	-40.687
Empleados	733
EBITDA	-275M -47M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+66.47% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-332M 2.5B
Apertura anterior	18.87
Cierre anterior	18.82

Noticias sobre sentimiento de mercado

By Acuity

49%

51%

149 / 351 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 mar 2026, 21:37 UTC

Adquisiciones, fusiones, absorciones

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Noticias de Eventos Importantes

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Charlas de Mercado

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Charlas de Mercado

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Adquisiciones, fusiones, absorciones

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Noticias de Eventos Importantes

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Charlas de Mercado

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Noticias de Eventos Importantes

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Charlas de Mercado

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Charlas de Mercado

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Charlas de Mercado

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Noticias de Eventos Importantes

Trump Ends News Conference

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

66.47% repunte

Estimación a 12 meses

Media 31.53 USD 66.47%

Máximo 48 USD

Mínimo 18 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

149 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.